基本情報
- CAS
145733-36-4- 標準SMILES
Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nn[nH]n3)cc1)C(=O)CC2- InChIKey
ADXGNEYLLLSOAR-UHFFFAOYSA-N- 分子式
- C23H21N7O
- 平均分子量
- 411.5 g/mol
- 単同位体質量
- 411.18075832
概要
Tasosartan is a member of biphenyls.
名称と識別子
- 優先名称
- Tasosartan
- IUPAC
- 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
- 現地名
- タソサルタン
- 英語名
- Tasosartan
- 分子式
- C23H21N7O
- 分子量
- 411.46
名称と別名
TASOSARTAN145733-36-4ANA-756WAY-ANA-756taso-sartanANA75648G92V856HDTXSID401631482,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-onetasosartanum2,4-dimethyl-8-((4-(2-(2H-1,2,3,4-tetrazol-5-yl)phenyl)phenyl)methyl)-5H,6H,7H,8H-pyrido(2,3-d)pyrimidin-7-one
名称をさらに表示
タソサルタン8-[2′-(1H-テトラゾール-5-イル)-4-ビフェニリルメチル]-2,4-ジメチル-5,6-ジヒドロピリド[2,3-d]ピリミジン-7(8H)-オン2,4-ジメチル-8-{[2'-(1H-1,2,3,4-テトラゾール-5-イル)-[1,1'-ビフェニル]-4-イル]メチル}-5H,6H,7H,8H-ピリド[2,3-d]ピリミジン-7-オン8-[[2′-(1H-テトラゾール-5-イル)-1,1′-ビフェニル-4-イル]メチル]-5,8-ジヒドロ-2,4-ジメチルピリド[2,3-d]ピリミジン-7(6H)-オンVerdiaCS-160DB01349AC1Q6LAAAC1L1U5XTasosartaS1539_Selleck
2,4-dimethyl-8-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)-5,6-dihydropyrido(6,5-d)pyrimidin-7-one2,4-dimethyl-8-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-5H,6H,7H,8H-pyrido[2,3-d]pyrimidin-7-oneRefChem:891190DTXCID3085639C09CA052,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-oneCHEMBL4321625,8-dihydro-2,4-dimethyl-8-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]pyrido[2,3-d]pyrimidin-7(6H)-one
物性
構造計算による物性
- XLogP
- 3
- 極性表面積
- 101 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 6
- 回転可能結合数
- 4
- 重原子数
- 31
- 形式電荷
- 0
- 複雑度
- 625
実験および物理化学的性質
DrugsPharmaceuticals -> Listed in ZINC15
Solubility3.25e-02 g/L
Physical DescriptionSolid
物理化学的性質
- 融点
- 197 · 197-199°
- 沸点
- 759.4 · 759.4±70.0 °C(Predicted)
- 比重(密度)
- 1.328 · 1.328±0.06 g/cm3(Predicted)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- DMSO（わずかに）、メタノール（わずかに、超音波処理）
- 外見
- 個体
- 酸解離定数(Pka)
- 4.16 · 4.16±0.10(Predicted)
- 色
- ホワイトからオフホワイト
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Tasosartan
vMost-DILI-concern
8
Discontinued
DOI:10.1016/j.drudis.2016.02.015
安全データ
- 危険有害性情報
- コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H315
化学と産業
薬理情報
ATC Code
C - Cardiovascular system
QC - Cardiovascular system
Pharmacodynamics
By blocking the angiotensin II (AT1) receptor, the drug ultimately causes vasodilation, reduced secretion of vasopressin (ADH), reduced production and secretion of aldosterone, amongst other actions leading to the combined effect of a reduction of blood pressure.
Mechanism of Action
Tasosartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Tasosartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Tasosartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
Metabolism/MetabolitesTasosartan has known human metabolites that include enoltasosartan.
MeSH Pharmacological ClassificationAgents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
Cellular LocationsMembrane
応用分野
使用Tasosartan is an angiotensin II receptor antagonist.
上流・下流製品情報
上流原料
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…